Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of GLPG2451 and of the Combination of GLPG2451 and GLPG2222 in Healthy Male Subjects

Next Previous
Trial Profile

Assessment of Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of GLPG2451 and of the Combination of GLPG2451 and GLPG2222 in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galicaftor (Primary) ; GLPG 2451 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Galapagos NV; Lakefront Biotherapeutics

Most Recent Events

  • 07 May 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
  • 12 Sep 2017 Status changed from active, no longer recruiting to completed.
  • 15 Jul 2017 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top